Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences establishes scientific advisory board

The board will provide scientific oversight and strategic advice to Metrion

Contract research organisation and drug discovery business Metrion Biosciences has established a scientific advisory board, which will provide strategic scientific guidance to the company.

The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

Dr Reynolds has served in numerous positions at Merck, Lundbeck and Pfizer.

Dr Tom Colatsky also joins the board following over 30 years of drug discovery experience, including seven years in senior US Food and Drug Admistration positions.

The board will also comprise of Professor Annette Dolphin, Professor Chris Denning and Marc Rogers, who is currently chief scientific officer at Metrion.

20th February 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics